Multiple Myeloma Hub

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM).  In this presentation, Popat discusses the importance of health-related QoL as a key clinical outcome in MM, particularly in the context of increasingly effective therapies. Popat emphasizes the need to balance efficacy and safety with QoL and outlines patient-, disease-, and treatment-related factors that influence QoL. Practical considerations, including treatment logistics, adverse events, and patient preferences, are also discussed, alongside approaches to assessing QoL and incorporating shared decision-making into clinical practice. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. 

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The session covered mechanisms of resistance with BCMA-targeted therapies; the impact of prior exposure to BCMA-directed therapies; the main differences between BCMA-directed antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies in terms of access, logistics, and toxicity profiles; and how dosing schedules can be adapted to optimize efficacy while limiting toxicity. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Maria Victoria Mateos provided an overview of the potential future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment paradigm. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Gordon Cook, University of Leeds, UK, delivered a presentation covering real-world insights and clinical experience with BCMA-directed therapies.In this presentation, Cook examined how populations enrolled in pivotal trials of BCMA-directed therapies compare with patients treated in routine clinical practice. Key differences were highlighted, including age, performance status, comorbidities, and prior treatment exposure. Cook presented data for bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, focusing on efficacy and safety outcomes in real-world populations as well as the impact of prior BCMA exposure on response and durability of response. Real-world experience with adverse events, particularly infections and ocular complications, was also discussed, as were the implications of these findings for treatment sequencing as BCMA-directed therapies move into earlier lines of therapy.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Marc-Andrea Bärtsch, Heidelberg University Hospital, DE, delivered a presentation on the current applications of BCMA-directed therapies in multiple myeloma (MM) and the evolving clinical landscape. In this presentation, Bärtsch discussed the rationale for targeting BCMA in MM and reviewed pivotal clinical trial data supporting the approval of BCMA-directed therapies. Bärtsch outlined the mechanisms of action, clinical positioning, and key efficacy and safety findings for antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies, highlighting differences in availability, toxicity profiles, and durability of response across treatment modalities and lines of therapy.This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.

The Multiple Myeloma Hub spoke with Mehmet Hakan Kocoglu, University of Maryland, Baltimore, US. We asked, What are the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM? In this interview, Mehmet Hakan Kocoglu discussed the latest updates from the phase I trial of P-BCMA-ALLO1 for RRMM, focusing on the key efficacy and safety data for this allogeneic BCMA-directed CAR T-cell therapy. This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.